摘要
目的探讨布地奈德联合复方异丙托溴铵雾化吸入对慢性阻塞性肺疾病急性加重期(AECOPD)患者肺功能及血清相关指标的影响。方法将我院2012年12月至2018年2月收治的150例AECOPD患者以随机数字表法分为观察组与对照组,各75例。对照组予以注射用甲泼尼龙琥珀酸钠静滴治疗,观察组在对照组基础上加用布地奈德+复方异丙托溴铵雾化吸入治疗,均治疗1周。对比两组的临床疗效、治疗前及治疗1周后的肺功能指标、血气指标及血清炎性因子指标水平。结果观察组的治疗总有效率高于对照组(P<0.05)。治疗1周后,两组患者的FEV1、FVC水平及FEV1/FVC均显著升高,且观察组高于对照组(P<0.05)。治疗1周后,两组患者的PaCO2水平均降低、PaO2水平均升高,且观察组优于对照组(P<0.05)。治疗1周后,两组患者的血清PCT及CRP水平均显著降低,且观察组低于对照组,差异具有统计学意义(P<0.05)。结论采用布地奈德联合复方异丙托溴铵雾化吸入治疗AECOPD可明显增强疗效,改善患者的肺功能与血气指标,减轻机体炎症反应。
Objective To investigate the effects of aerosol inhalation of budesonide combined with compound ipratropium bromide on pulmonary function and serum related indexes in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD). Methods A total of 150 patients with AECOPD admitted in our hospital from December2012 to February 2018 were randomly divided into observation group and control group, with 75 cases in each group. The control group was treated with intravenous drip of methylprednisolone sodium succinate for injection, while the observation group was treated with aerosol inhalation of budesonide combined with compound ipratropium bromide on the basis of the control group. Both groups were treated for one week. The clinical efficacy, levels of pulmonary function indexes, blood gas indexes and serum inflammatory factor indexes before treatment and after one week of treatment were compared between the two groups. Results The total effective rate of treatment in the observation group was higher than that in the control group(P <0.05). After one week of treatment, the levels of FEV1, FVC and FEV1/FVC in the two groups significantly increased, and those of the observation group were higher than the control group(P<0.05). After one week of treatment, the PaCO2 levels in both groups decreased and PaO2 levels increased, and those of the observation group were better than the control group(P<0.05). After one week of treatment, the levels of serum PCT and CRP in both groups significantly decreased,and those of the observation group were lower than the control group(P<0.05). Conclusion Aerosol inhalation of budesonide combined with compound ipratropium bromide in the treatment of AECOPD can significantly enhance the curative effect,improve the pulmonary function and blood gas indexes of patients, and alleviate the body inflammatory reaction.
作者
杨敏娥
柳胜陇
YANG Min-e;LIU Sheng-long(Respiratory Department,Changqing Oilfield Staff Hospital,Xi'an 710201,China;Critical Care Medicine Department,Changqing Oilfield Staff Hospital,Xi'an 710201,China)
出处
《临床医学研究与实践》
2019年第14期25-27,共3页
Clinical Research and Practice
关键词
慢性阻塞性肺疾病急性加重期
布地奈德
复方异丙托溴铵
肺功能
acute exacerbation of chronic obstructive pulmonary disease
budesonide
compound ipratropium bromide
pulmonary function